Pembrolizumab
Lung cancer trial halted due to lack of survival benefit, higher toxicity
A randomized phase 3 trial designed to compare two combinations for first-line treatment of lung cancer has been halted after an interim analysis revealed no survival benefit and more toxicity with the experimental regimen.
Trial of vaccine plus pembrolizumab for head/neck cancer misses endpoint
The addition of an investigational cancer vaccine to pembrolizumab failed to improve outcomes for patients with metastatic or recurrent head and neck squamous cell carcinoma, according to the agent’s manufacturer.
Tecentriq combination fails to improve survival in metastatic lung cancer
Tiragolumab plus atezolizumab added to chemotherapy did not extend survival outcomes as first-line therapy of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, interim results from a randomized study showed.
FDA approves Keytruda regimen for advanced endometrial cancer
The FDA approved the use of pembrolizumab in combination with chemotherapy for adults with primary advanced or recurrent endometrial carcinoma.
Adding mRNA vaccine to immunotherapy cuts risk for melanoma recurrence nearly in half
CHICAGO — Combining an mRNA-based cancer vaccine with standard-of-care pembrolizumab significantly improved RFS and distant metastasis-free survival among patients with resected high-risk melanoma, study results showed.
Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma
CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.
‘There may be a role’ for frontline lifileucel plus pembrolizumab in advanced melanoma
CHICAGO — A front-line treatment regimen including lifileucel and pembrolizumab produced ongoing durable responses in some patients with unresectable or metastatic melanoma, according to findings presented at ASCO Annual Meeting.
Vibostolimab, pembrolizumab coformulation trial discontinued for resected high-risk melanoma
Merck has discontinued the vibostolimab and pembrolizumab coformulation arm of its phase 3 trial for the adjuvant treatment of patients with resected high-risk melanoma, the company announced in a press release.
Setanaxib-pembrolizumab combination extends survival in advanced head and neck cancer
The addition of setanaxib to pembrolizumab in adults with squamous cell carcinoma of the head and neck conferred significant improvement in both PFS and OS, according to a topline data release from the agent’s manufacturer.
Keytruda-based regimen extends survival in advanced gastric cancer
A regimen of pembrolizumab plus trastuzumab and chemotherapy extended OS for individuals with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.